510(k) Summary AMS Perigee™ System

page 10f2

510(k) Number <u>K040623</u>

Date of Summary Preparation:

March 8, 2004

Submitter/Contact Person:

Elsa A. Linke Regulatory Affairs Specialist American Medical Systems 10700 Bren Rd. W Minnetonka, MN 55343

Phone: (952) 930-6000 Fax: (952) 930-6496

Device Name and Classification:

Trade Name: AMS Perigee™ System Common/Usual Name: Surgical Mesh

Classification Name: Surgical Mesh, polymeric

Product Code: FTL Classification: Class II

Manufacturing Location:

American Medical Systems, Inc. 10700 Bren Rd. West Minnetonka, MN 55343

Predicate Devices:

AMS Sparc Sling System – K011251
AMS Monarc Sling System – K023516
AMS BioArc – K030123
AMS Large Pore Polypropylene Mesh – K033636, K040521

Indications for Use:

The Perigee™ System is intended for the placement of graft material in the anterior vaginal wall via the obturator foramen for the treatment of anterior vaginal wall prolapse.

Device Description:


The Perigee™ System consists of needles and connectors used to pass a polypropylene mesh for support of the anterior vaginal wall.

Summary of Testing

The mesh used in the Perigee™ System has been tested in accordance with FDA's Guidance for the Preparation of a Premarket Notification Application for a Surgical Mesh and has been shown to be equivalent to the listed predicate devices. In

K040623 page 2 of 2

addition, the other components have demonstrated substantial equivalence to the predicate devices in terms of mechanical performance and biocompatibility.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAY 1 7 2004

Ms. Elsa A. Linke Regulatory Affairs Specialist American Medical Systems 10700 Bren Road W. Minnetonka, Minnesota 55343

Re: K040623

Trade/Device Name: AMS Perigee™ System Regulation Number: 21 CFR 878.3300 Regulation Name: Surgical mesh, polymeric

Regulatory Class: II Product Code: FTL Dated: March 8, 2004 Received: March 9, 2004

Dear Ms. Linke:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Muram C Provost For Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

510(k)	Number (if known):	K040623	
	Name: AMS Perig	•	
Indications for Use: The Perigee™ System is intended for the placement of graft material in the anterior vaginal wall via the obturator foramen for the treatment of anterior vaginal wall prolapse.			
Prescri (Per 21 (ption UseX CFR 801 Subpart D)	AND/OR	Over-The Counter Use(21 CFR 807 Subpart C)
(PLEA IF NEE		BELOW THIS LINE-CO	ONTINUE ON ANOTHER PAGE
	Concurrence o	f CDRH, Office of Device	e Evaluation (ODE)
	<u>Murua</u> (Division S	im C. Provost Sign-Off)	
		f General, Restocativ	
	and Neuro	logical Devices	Page 1 of <u>1</u>
	510(k) Nu	mber_ <i>K040623</i>	